Skip to main content
Caplight Logo









IMPACT Therapeutics

IMPACT Therapeutics

Public

IMPACT Therapeutics is now publicly traded

The data on this page reflects IMPACT Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Mar 27, 2026

Last Round

Series D

Extension

Nov 15, 2024

Total Funding Raised

$169.7M

Company Overview

IMPACT Therapeutics is a biotechnology company that develops synthetic lethality-based precision anti-cancer therapies.

AI Layer

Non-AI

Keywords

oncology therapeuticssynthetic lethalitytargeted cancer therapyDNA damage responseDDRPARP inhibitorsmall-molecule drugprecision medicinedrug discoverybiotechWEE1 inhibitorDHODH inhibitorclinical-stage biotechcancer drug pipelinepharma licensing

IMPACT Therapeutics Comparables

Compare IMPACT Therapeutics with similar companies based on industry and business-model similarity.

IMPACT Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HaiHe Biopharma
79%
SynRx Therapeutics
76%
成都赜灵生物医药科技有限公司
66%

IMPACT Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOMar 27, 2026
Series D ExtensionNov 15, 2024
Series D ExtensionApr 22, 2024
Series DMar 14, 2022
Series C ExtensionNov 30, 2020
Series C
Aug 3, 2018

IMPACT Therapeutics Investors

Notable investors and investment history

IMPACT Therapeutics investors
InvestorRounds
Dingxin CapitalSeries D
Xiamen C&D Emerging Industry Equity InvestmentSeries D Extension
Exome Asset ManagementSeries D
Lilly Asia VenturesSeries D, Series D Extension, Series C Extension, Series C
Decheng CapitalSeries C

Recent news

Latest coverage and updates

  • partners_withJul 31, 2026

    IMPACT Therapeutics was planning to partner with Pharmanovia, company on Jul 31st '26.

  • attends_eventJul 20, 2026

    IMPACT Therapeutics will attend event ESMO 2026 on Oct 23rd '26.

  • attends_eventJul 20, 2026

    IMPACT Therapeutics plans to attend event 2026 European Society for Medical Oncology (ESMO) Congress on Oct 23rd '26.

IMPACT Therapeutics Filings

Explore SEC and related filing metadata, where available.

IMPACT Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

Headquarters—
Employee Range2
Year Founded2009
Last FundingNov 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?